Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 0 |
| Since 2007 (last 20 years) | 3 |
Descriptor
| Behavior Problems | 4 |
| Autism | 3 |
| Children | 3 |
| Comparative Analysis | 3 |
| Drug Therapy | 3 |
| Hyperactivity | 3 |
| Pervasive Developmental… | 3 |
| Check Lists | 2 |
| Compliance (Psychology) | 2 |
| Outcomes of Treatment | 2 |
| Pharmacology | 2 |
| More ▼ | |
Author
| Aman, Michael G. | 4 |
| Arnold, L. Eugene | 4 |
| McDougle, Christopher J. | 2 |
| Scahill, Lawrence | 2 |
| Bearss, Karen | 1 |
| Cook, Amelia M. | 1 |
| Deng, Yanhong | 1 |
| Dziura, James | 1 |
| Farmer, Cristan | 1 |
| Hall, Kristy L. | 1 |
| Hallett, Victoria | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 4 |
| Reports - Research | 4 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 4 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkScahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto – Journal of Autism and Developmental Disorders, 2013
There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to…
Descriptors: Autism, Pharmacology, Effect Size, Pervasive Developmental Disorders
Farmer, Cristan; Lecavalier, Luc; Yu, Sunkyung; Arnold, L. Eugene; McDougle, Christopher J.; Scahill, Lawrence; Handen, Benjamin; Johnson, Cynthia R.; Stigler, Kimberly A.; Bearss, Karen; Swiezy, Naomi B.; Aman, Michael G. – Journal of Autism and Developmental Disorders, 2012
The Research Units on Pediatric Psychopharmacology-Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The "Home Situations…
Descriptors: Behavior Problems, Autism, Hyperactivity, Predictor Variables
Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene – Research in Developmental Disabilities: A Multidisciplinary Journal, 2009
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…
Descriptors: Metabolism, Behavior Problems, Reaction Time, Hyperactivity
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Arnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
